Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies

Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. J Med Virol. 2013;85(6):1019-1027.

Publication Type:

Journal Article

Authors:

Fabrizi, F.; Dixit, V.; P Messa

Source:

J Med Virol, Volume 85, Issue 6, p.1019-1027 (2013)

Keywords:

Adult, Aged, analysis, Antiviral Agents, clinical trial, Clinical Trials, complications, Controlled Clinical Trials, Cryoglobulinemia, Developed Countries, drug effects, drug therapy, Drug Therapy,Combination, Female, HCV, Hepacivirus, hepatitis, Hepatitis C, hepatitis C virus, Hepatitis C,Chronic, Humans, Infection, Interferon-alpha, Italy, Kidney, Male, Middle Aged, Models,Statistical, Patients, peginterferon, peginterferon alfa-2b, pegylated, physiopathology, Polyethylene Glycols, Proteins, Recombinant Proteins, Research, Research Support, Ribavirin, Safety, secondary, systematic review, therapeutic use, therapy, treatment, Treatment Outcome, virology

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/23588727

Export Citation:

RIS Format

Top